The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival

Annals of Oncology

Volumn 23, Issue 1, 2012, Pages 78-85

  William, W N ^a   Kim, J S ^a   Liu, D D ^a   Solis, L ^a   Behrens, C ^a   Lee, J J ^a   Lippman, S M ^a   Kim, E S ^a   Hong, W K ^a   Wistuba, I I ^a   Lee, H Y ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Seoul National University   (South Korea)

Author keywords

AMP activated protein kinase; LKB1; Non small cell lung cancer; Tobacco smoking

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SMOKING; SURVIVAL TIME; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; AMP-ACTIVATED PROTEIN KINASES; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855180734     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr036     Document Type: Article

References (30)

1. Hardie DG, Carling D. The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem 1997; 246: 259-273.
2. Hong SP, Leiper FC, Woods A et al. Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc Natl Acad Sci U S A 2003; 100: 8839-8843.
3. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295.
4. Minokoshi Y, Kim YB, Peroni OD et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415: 339-343.
5. Luo Z, Saha AK, Xiang X, Ruderman NB. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005; 26: 69-76.
6. Rattan R, Giri S, Singh AK, Singh I. 5-Aminoimidazole-4-carboxamide-1-beta-Dribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMPactivated protein kinase. J Biol Chem 2005; 280: 39582-39593.
7. Kimura N, Tokunaga C, Dalal S et al. A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells 2003; 8: 65-79.
8. Jin Q, Feng L, Behrens C et al. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res 2007; 67: 11630-11639.
9. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006; 25: 6416-6422.
10. Tiainen M, Ylikorkala A, Makela TP. Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. Proc Natl Acad Sci U S A 1999; 96: 9248-9251.
11. Carretero J, Medina PP, Blanco R et al. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene 2007; 26: 1616-1625.
12. Giardiello FM, Brensinger JD, Tersmette AC et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119: 1447-1453.
13. Sanchez-Cespedes M, Parrella P, Esteller M et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002; 62: 3659-3662.
14. Ji H, Ramsey MR, Hayes DN et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448: 807-810.
15. Yuan P, Kadara H, Behrens C et al. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One 2010; 5: e9112.
16. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1717.
17. Li J, Jiang P, Robinson M et al. AMPK-beta1 subunit is a p53-independent stress responsive protein that inhibits tumor cell growth upon forced expression. Carcinogenesis 2003; 24: 827-834.
18. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther 2006; 5: 430-437.
19. Han S, Khuri FR, Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 2006; 66: 315-323.
20. Ido Y, Carling D, Ruderman N. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 2002; 51: 159-167.
21. Park HU, Suy S, Danner M et al. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 2009; 8: 733-741.
22. Conde E, Suarez-Gauthier A, Garcia-Garcia E et al. Specific pattern of LKB1 and phospho-acetyl-CoA carboxylase protein immunostaining in human normal tissues and lung carcinomas. Hum Pathol 2007; 38: 1351-1360.
23. Hahn-Windgassen A, Nogueira V, Chen CC et al. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 2005; 280: 32081-32089.
24. West KA, Brognard J, Clark AS et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003; 111: 81-90.
25. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
26. Racanelli AC, Rothbart SB, Heyer CL, Moran RG. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 2009; 69: 5467-5474.
27. Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
28. Matsumoto S, Iwakawa R, Takahashi K et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007; 26: 5911-5918.
29. Onozato R, Kosaka T, Achiwa H et al. LKB1 gene mutations in Japanese lung cancer patients. Cancer Sci 2007; 98: 1747-1751.
30. Koivunen JP, Kim J, Lee J et al. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer 2008; 99: 245-252.